Travere Therapeutics Inc (TVTX) News Headlines

▮ More

Date

Headline

2/18/2023 8:45:33 AM FDA Grants Accelerated Approval To Travere's Filspari For IgA Nephropathy Treatment

1/29/2023 6:18:56 AM Biotech Stocks Facing FDA Decision In February 2023

10/28/2022 9:36:23 AM ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook

3/8/2022 10:57:31 AM Travere Therapeutics Stock Slips 15%

9/16/2021 1:26:01 AM Vifor Pharma, Travere Reach Deal For Commercialization Of Kidney Disease Medicine Sparsentan

9/16/2021 1:04:29 AM Vifor Pharma, Travere Announce Licensing Deal For Commercialization Of Sparsentan In Europe, Australia And New Zealand

5/26/2021 12:49:52 AM LRMR Hit By 'double Whammy', PRVB On Watch, TLC Comes To India's Rescue To Fight Black Fungus

2/3/2021 12:41:37 AM SAVA Jumps From $7 To $75 In Just 3 Weeks, DRRX Gets FDA Nod, IMVT Pauses Trials, OCGN Catches Eye

2/2/2021 10:01:19 AM Stock Alert: Travere Therapeutics Hits New High; Positive News On Drug Candidate Sparsentan

1/11/2021 7:28:15 AM Travere Expects Net Product Sales For Q4 To Be $51 Mln

4/6/2017 7:10:50 AM William Blair Starts Retrophin Inc. (RTRX) At Outperform

5/12/2015 12:29:20 PM Deutsche Bank Reiterates Retrophin Inc. (RTRX) At Buy With $50 Price Target

4/28/2015 12:19:47 PM Deutsche Bank Initiates Retrophin Inc. (RTRX) At Buy With $50 Price Target

Older Articles